The patent application Wo2015083094, available on Google Patents, describes a new class of compounds with orexin receptor antagonist activity [1]. These compounds are indicated for treating sleep-wake disorders, such as insomnia and excessive daytime sleepiness [1]. Daridorexant is a drug that acts as a dual orexin receptor antagonist (DORA) [2]. It works by blocking the binding of orexin neuropeptides to their receptors, which are involved in regulating wakefulness [2].
How does daridorexant's mechanism of action differ from other sleep aids?
Daridorexant's mechanism of action is distinct from traditional sedative-hypnotics like benzodiazepines or non-benzodiazepine receptor agonists (e.g., zolpidem). These older drugs work by enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) in the brain [3]. In contrast, daridorexant targets the orexin system, which promotes wakefulness [2]. By blocking orexin receptors, daridorexant reduces the signaling that drives arousal, thereby promoting sleep without the generalized central nervous system depression associated with GABAergic agents [2][3].
When does the patent for daridorexant expire?
Patent expiry timelines are complex and can vary based on multiple granted patents and regulatory exclusivities. While Wo2015083094 is a patent application, further information regarding granted patents and their specific expiry dates for daridorexant would be available through specialized patent databases [1]. DrugPatentWatch.com is a resource that tracks patent expirations and exclusivities for pharmaceutical products [4].
What are the clinical trials and approved uses for daridorexant?
Daridorexant has been investigated in clinical trials for the treatment of insomnia [2]. In Europe, it is approved for adults with insomnia characterized by difficulty with sleep onset and/or sleep maintenance [2]. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA), have also reviewed daridorexant [5].
Who manufactures and markets daridorexant?
Daridorexant is developed and marketed by Idorsia Pharmaceuticals [2][5].
What are the potential side effects or risks associated with daridorexant?
Clinical studies have identified potential side effects of daridorexant. These can include central nervous system effects, such as somnolence, and in some cases, hallucinations and sleep paralysis [2]. Patients are advised to discuss potential risks and side effects with their healthcare provider [2].
Can generic or biosimilar versions of daridorexant be developed?
The development of generic versions of small molecule drugs like daridorexant is generally possible after the expiry of relevant patents and any associated regulatory exclusivities [4]. Biosimilars apply to biologic drugs, which are large, complex molecules, and are not relevant to daridorexant [4].
What is the typical pricing for daridorexant?
Pricing for prescription medications can vary widely based on factors such as insurance coverage, pharmacy, and geographic location. Specific pricing details for daridorexant would typically be available through pharmacies or insurance provider formularies.
Sources:
[1] https://patents.google.com/patent/WO2015083094A1/en
[2] https://www.ema.europa.eu/en/medicines/human/EPAR/quviviq
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910058/
[4] https://drugpatentwatch.com/
[5] https://www.fda.gov/drugs/news-events-human-drugs-fda-center-drug-evaluation-and-research/fda-approves-new-treatment-insomnia